Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report

被引：104

作者：

Goldman, Stanton ^{[1
]}

Smith, Lynette ^{[2
]}

Galardy, Paul ^{[3
]}

Perkins, Sherrie L. ^{[4
]}

Frazer, John Kimble ^{[5
]}

Sanger, Warren ^{[6
]}

Anderson, James R. ^{[2
]}

Gross, Thomas G. ^{[7
]}

Weinstein, Howard ^{[8
]}

Harrison, Lauren ^{[9
]}

Shiramizu, Bruce ^{[10
]}

Barth, Matthew ^{[11
]}

Cairo, Mitchell S. ^{[9
,12
,13
,14
,15
]}

机构：

[1] Med City Childrens Hosp, Div Pediat Hematol Oncol, Dallas, TX USA

[2] Univ Nebraska, Coll Publ Hlth, Dept Biostat, Omaha, NE 68182 USA

[3] Mayo Clin, Dept Pediat Hematol Oncol, Rochester, MN USA

[4] Univ Utah, Dept Pathol, Salt Lake City, UT USA

[5] Univ Oklahoma, Hlth Sci Ctr, Sect Pediat Hematol Oncol, Oklahoma City, OK USA

[6] Univ Nebraska, Ctr Human Genet, Omaha, NE 68182 USA

[7] NCI, Ctr Global Hlth, NIH, Rockville, MD USA

[8] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pediat Hematol Oncol, Boston, MA USA

[9] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA

[10] Univ Hawaii, Div Pediat Hematol Oncol, Honolulu, HI 96822 USA

[11] Roswell Pk Canc Inst, Dept Pediat, Buffalo, NY 14263 USA

[12] New York Med Coll, Dept Med, Valhalla, NY 10595 USA

[13] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA

[14] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA

[15] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 167卷 / 03期

基金：

美国国家卫生研究院;

关键词：

children; Burkitt lymphoma; Burkitt leukaemia; chemotherapy; rituximab; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; ACUTE-LYMPHOBLASTIC-LEUKEMIA; PLUS RITUXIMAB; ADULT BURKITT; CODOX-M/IVAC; PHASE-II; RISK; INTERMEDIATE; THERAPY;

D O I：

10.1111/bjh.13040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375mg/m(2)) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease +/- leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3-year event-free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76-96%) in the entire cohort and 93% (95% CI, 61-99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy +/- rituximab for high-risk patients is currently under investigation.

引用

页码：394 / 401

页数：8

共 22 条

[21]

Vardiman JW., 2008, WHO CLASSIFICATION T

[22] The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95 [J].

Woessmann, W ;

Seidemann, K ;

Mann, G ;

Zimmermann, M ;

Burkhardt, B ;

Oschlies, I ;

Ludwig, WD ;

Klingebiel, T ;

Graf, N ;

Gruhn, B ;

Juergens, H ;

Niggli, F ;

Parwaresch, R ;

Gadner, H ;

Riehm, H ;

Schrappe, M ;

Reiter, A .

BLOOD, 2005, 105 (03) :948-958

← 1 2 3 →